MedTrace Logo

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-02-21

No results posted yet for this study

Summary

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.

Conditions

  • Myelofibrosis
  • Primary Myelofibrosis
  • Post-PV MF
  • Post-ET Myelofibrosis

Interventions

DRUG

TL-895

TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

DRUG

Ruxolitinib

Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.

Sponsors & Collaborators

  • Telios Pharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-09
Primary Completion
2025-10-31
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05280509 on ClinicalTrials.gov